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Hematopoietic stem cell transplantation (HSCT) recipients are a high-risk, immunocompromised group of
patients who receive frequent transfusions after transplantation. Transfusion of cytomegalovirus (CMV)-
negative blood products has long been the standard of care to prevent transfusion-transmitted CMV in this
patient population. Leukoreduction of blood products before transfusion has been shown to signiﬁcantly
reduce the risk of transfusion-transmitted CMV. In the era of universal leukoreduction in Canada, the need for
CMV testing of blood products remains unclear. We sought to identify whether there is a difference in
transfusion-transmitted CMV viremia in patients receiving only leukoreduced versus CMV-negative and
leukoreduced blood products in HSCT recipients. Patients who were CMV negative and received an allogeneic
HSCT from a CMV-negative donor between October 1, 1999 and June 30, 2012 were included in the analysis.
Transfusion data were collected from The Ottawa Hospital Blood Bank and Canadian Blood Services. CMV
viremia was deﬁned as PCR positivity. One hundred sixty-six patients were identiﬁed who met the inclusion
criteria. Of these, 89 patients received an HSCT before January 2007, during the time when patients received
leukoreduced and CMV-negative blood products. Seventy-seven patients received an HSCT after this time,
receiving only leukoreduced blood products. The 2 groups did not differ in terms of age, gender, diagnosis,
graft type, graft source, conditioning regimen, or ABO compatibility (P > .05). CMV viremia was detected in 3
patients who received CMV-negative leukoreduced blood products (3.37%) and in 1 patient who received only
leukoreduced blood products (1.30%, P ¼ .6244). Of the patients who developed CMV viremia, 2 developed
suspected CMV disease. Both of these patients were transfused with CMV-negative blood products. Secondary
outcomes, including total length of stay in hospital, admission to the intensive care unit, acute and chronic
graft versus host disease, and 100-day nonrelapse mortality, did not differ between the groups. In the era of
universal leukoreduction of blood products, this study demonstrates that testing for CMV-negative blood
products is not needed for HSCT recipients.
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Transfusion practices over the years have drastically
changed to improve the quality and safety of products
transfused. One such change has been the implementation of
universal leukocyte reduction of all transfused red cell and
platelet products in Canada beginning in 1999. This was
implemented after leukoreduction was shown in studies to
decrease the incidence of febrile nonhemolytic transfusion
reactions by approximately half, from .33% to .37% in red
blood cell (RBC) [1-3] transfusion and from .18% to .19% in
platelet [1,4,5] transfusions. Furthermore, multiple studies
have shown that leukocyte reduction decreases the rate of
alloimmune platelet refractoriness [6].
Cytomegalovirus (CMV) transmission is a recognized
complication of blood transfusions. CMV is a DNA virus that,
after primary infection, remains in a latent form. Sites of la-
tency are believed to include bone marrow progenitor cells
and monocytes. Prevalence of CMV antibodies in the generaldgments on page 1724.
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13.09.013adult population ranges from 40% to 100% [7], with some
studies showing a higher prevalence among men, people
from a lower socioeconomic status, and at an increasing age
[8]. In Canada, the seroprevalence has been estimated at 60%
to 70% [8].One Canadian study showed that CMV seropre-
valence among daycare workers was associated with
increasing patient age, interaction with children, and low
income birth country [9].
Transfusion-transmitted CMV infection in transfusion
recipients who are immunocompetent is uncommon, re-
ported to be about 1% [10]. This incidence is thought to be
higher in immunocompromised patients, including he-
matopoietic stem cell transplantation (HSCT) recipients [11].
The most signiﬁcant disease manifestations of CMV in HSCT
recipients are pneumonia and gastrointestinal disease, both
of which are associated with signiﬁcant morbidity and
mortality in these patients [9]. CMV pneumonia in HSCT
recipients has been associated with mortality in 85% to 90%
of these patients [12,13]. With pre-emptive treatment with
antivirals, this has become much less common [14,15].
Efforts have been made to decrease the risk of CMV
transmission via blood product transfusion in high-risk pa-
tients such as HSCT recipients. One landmark study in the
1980s identiﬁed that the use of CMV-seronegative bloodTransplantation.
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infection by 21% in CMV-seronegative HSCT recipients when
compared with standard, non-leukoreduced blood product
use [16]. The standard of care since then has been to provide
CMV-seronegative blood products to HSCT recipients.
The introduction of universal leukoreduction of blood
products has resulted in a move away from this standard in
some transplant centers. In Canada, currently the practice is
divided in that half of transplant centers continue to require
CMV-negative blood products for allogeneic HSCT recipients
(S. Couban, M. Seftel, R. Foley, D. Stewart, and J. Sepher,
personal communication by Internet survey through the
Canadian Blood and Marrow Transplant Group, June 2012).
There have been conﬂicting reports as to whether leukore-
duced blood products are as effective at preventing
transfusion-transmitted CMV as CMV-negative products
when transfusing high-risk patients. Bowden et al. [17]
demonstrated through a randomized prospective study
that bedside ﬁltration of leukocytes, an older, arguably less
effective, method of leukoreduction, was as effective as CMV-
seronegative blood products in preventing transfusion-
transmitted CMV infection in HSCT recipients. In contrast, a
prospective cohort study found transfusion of each addi-
tional ﬁltered RBC unit from CMV-positive blood donors was
associated with a 32% increase in the odds of developing
transfusion-transmitted CMV [18]. In addition to leukor-
eduction, PCR monitoring for CMV and effective pre-emptive
therapy with ganciclovir make it more unclear if there re-
mains a need to provide CMV-negative blood products to
HSCT recipients. We sought to identify whether there is a
difference in transfusion-transmitted CMV viremia and dis-
ease in patients receiving only leukoreduced versus CMV
tested negative and leukoreduced blood products in HSCT
recipients at The Ottawa Hospital.
METHODS
Patients and Transfusion Data
Weperformed an uncontrolled “beforeeafter” study using prospectively
collected institutional data. Patients included in the analysis were serologic
CMV-negative adults aged 18 years or older who received an allogeneic
HSCT from a CMV-negative donor at The Ottawa Hospital HSCT Program
between October 1, 1999 and June 30, 2012. Patient demographics included
age, gender, disease, graft type, graft source, related or unrelated match
status, degree of HLA match, ABO blood group compatibility, and condi-
tioning regimen. All patients provided consent for collection of relevant
health information for clinical research. Data were analyzed in an anony-
mous fashion in accordance with approval of The Ottawa Hospital Research
Ethics Board.
Transfusion data were collected from The Ottawa Hospital Blood Bank.
CMV status of transfused units was obtained from Canadian Blood Services.
As per Canadian Blood Services standards, all RBC and platelet products
were leukoreduced at collection before component storage. The use of
leukoreduced RBC and platelet products began at The Ottawa Hospital on
September 3, 1999 (P. Lesley, Canadian Blood Services, personal communi-
cation, 2013). As of January 1, 2007, as per change in policy at The Ottawa
Hospital, patients receiving an allogeneic HSCT received standard leukore-
duced products that were not speciﬁcally tested for CMV. Hereafter
throughout this study, patients who received only leukoreduced blood
products are referred to as leukoreduced, whereas patients who received
leukoreduced blood products that were tested to be CMV negative are
referred to as CMV negative. All patients in this study received irradiated
(25 Gy) blood products.
Clinical Outcomes
The primary outcome was CMV viremia, deﬁned as PCR positivity,
evaluated in all patients who met the above criteria. CMV testing was done
on a weekly basis after neutrophil and platelet engraftment after trans-
plantation until immune suppression was discontinued. CMV testing was
performed using the Amplicor CMV monitoring assay (Roche Diagnostics,
Branchburg, NJ). This assay has been used at our center since 1998. Amplicor
is an automated PCR assay using an enzyme immunoassay detection system.The linear range of the assay is 400 to 100,000 copies per milliliter. The
sensitivity and speciﬁcity of this Amplicor assay has previously been
established as 96% and 98%, respectively [19]. CMV disease was deﬁned as
tissue biopsyeproven CMV or CMV seropositivity with signs and symptoms
known to be associated with CMV, namely retinitis, ependymitis, hepatitis,
esophagitis, colitis, and pneumonia [20].
Secondary outcomes were total length of stay in hospital; admission to
the intensive care unit; time to neutrophil engraftment, deﬁned as a
neutrophil count > .5  109/L for at least 3 days; time to platelet engraft-
ment, deﬁned as a platelet count > 50  109/L with no platelet transfusions
for 3 days; incidence of grades II to IV acute graft-versus-host disease
(GVHD) at 100 days; incidence of chronic GVHD, reported for patients sur-
viving at least 100 days; 100-day nonrelapse mortality, deﬁned as death in
the absence of underlying disease within the ﬁrst 100 days; RBC transfusion
requirements during the 30 days after the marrow infusion; and platelet
transfusion requirements during the 30 days after marrow infusion. GVHD
was graded using standard published criteria [21].
Statistical Analysis
Baseline characteristics were described using measures of central ten-
dency and dispersionwhere appropriate. For the comparison of proportions,
chi-square or Fisher’s exact test were performed. Times to engraftment and
transfusion requirements were analyzed using Student’s t-test. Continuous
variables were analyzed using Wilcoxon rank test. All statistical analyses
were carried out using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
From October 1, 1999 to June 30, 2012, 166 patients were
identiﬁed who met inclusion criteria. Eighty-nine patients
received an HSCT before January 1, 2007, during the time
when patients received leukoreduced and CMV-negative
blood products. One hundred percent of patients in this
cohort received CMV-negative blood products alone.
Seventy-seven patients received an HSCT after this time,
receiving only leukoreduced blood products.
The 2 groups did not differ in terms of age or gender
(Table 1). There were no signiﬁcant differences in diagnoses,
graft type, graft source, conditioning regimen, or ABO
compatibility between the 2 groups (Table 1).
There was no difference in the incidence of CMV viremia
in those receiving CMV-negative versus leukoreduced blood
products. CMV viremia was detected in 3 patients who
received CMV-negative blood products (3.4; 95% conﬁdence
interval, .3% to 9.1%) and in 1 patient who received only
leukoreduced blood products (1.3; 95% conﬁdence interval,
.7% to 9.5%; P ¼ .62). Details of these 4 patients can be found
in Table 2. All 4 patients received treatment with i.v. ganci-
clovir. Of the patients who developed CMV viremia, 2
developed suspected CMV disease. Both of these patients
were transfused with CMV-negative blood products. One
developed CMV viremia and acute respiratory failure
requiring intensive care unit admission. This patient was
concomitantly diagnosedwith systemic Aspergillus fumigatus
infection requiring antifungal therapy. The second patient
also required admission to the intensive care unit for respi-
ratory failure and was diagnosed with concomitant HHV-6
viremia. Both patients died of respiratory failure.
The mean length of stay for patients receiving CMV-
negative versus leukoreduced only blood products was 41.5
and 46.8 days, respectively (P ¼ .47). The proportion of pa-
tients who went to the intensive care unit was also not
different in the 2 cohorts (P ¼ .10). Time to neutrophil and
platelet engraftment was not different between the 2 groups
(Table 3, Figures 1 and 2). The incidences of overall (any
grade) and severe (grades III to IV) acute GVHD were not
different in the 2 groups (P ¼ .39 and .13, respectively). The
incidence of chronic GVHD was 22.5% in patients receiving
CMV tested negative blood products versus 23.4% in patients
receiving only leukoreduced blood products (P¼ .52). Overall
Table 1
Patient Characteristics
CMV Negative (n ¼ 89) Leukoreduced (n ¼ 77) P
n % n %
Gender (% female) 27 30.3 30 39.0 .24
Age (mean  SD) 39.5  13.4 43.5  15.5 .07
Diagnosis
ALL 12 13.5 10 13.0 .18
AML 19 21.4 27 35.1
CML 14 15.7 2 2.6
Hodgkin lymphoma 6 6.7 5 6.5
Non-Hodgkin lymphoma 14 15.7 9 11.7
MDS/MPN 9 10.1 10 13.0
CLL 7 7.9 8 10.4
Plasma cell disorders 2 2.3 2 2.6
Other* 6 6.7 4 5.2
Graft type
PBSC 53 59.6 53 68.8 .21
BM 36 40.5 24 31.2
Graft source
Allo HLA match 46 51.7 30 39.0 .19
Allo HLA match unrelated 36 40.5 42 54.6
Allo HLA mismatched 7 7.9 5 6.5
Conditioning regimen
Myeloablative 70 78.7 53 68.8 .21
Nonmyeloablative 19 21.4 24 31.2
ABO mismatch 44 49.4 39 50.7 .88
30-Day transfusion needs (mean  SD; units)
SDP 9.6  11.8 8.8  10.8 .43
RDP 3.3  15.8 .5  2.6 .01
RBC 9.0  10.6 7.2  7.7 .23
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; MPN,
myeloproliferative neoplasm; CLL, chronic lymphocytic leukemia; PBSC, peripheral blood stem cells; BM, bone marrow; SDP, single-donor platelets; RDP,
random donor platelets.
* “Other” includes hemoglobinopathy, inherited disorders of metabolism, and nonhematologic malignancies.
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Figure 3). The 100-day mortality for patients receiving CMV-
negative blood products versus patients receiving only
leukoreduced blood products was 22.5% and 14.7%, respec-
tively (P ¼ .24).
At 30 days, the number of packed RBC transfusions and
single donor platelet units was not different (P ¼ .23 and .43,
respectively). There were, however, more transfusions of
random donor platelets to patients receiving CMV-negative
blood products versus those receiving leukoreduced-only
transfusions (mean 3.3 versus .5 units, respectively;
P ¼ .01). Of the patients who received leukoreduced-only
blood products, data were available on the CMV status of
all units transfused until day 30 after HSCT for 63 patients
(provided by Canadian Blood Services). The mean number of
CMV-negative RBC units transfused was 6.4  4.4, CMV-
positive RBC units was 1.9  1.4, CMV-negative platelet
units was 3.7  2.9, and CMV-positive platelet units was
4.1  3.0. Patient D with CMV viremia (Table 2) who received
leukoreduced-only blood products received 4 RBC units that
were CMV negative, 2 RBC units that were CMV positive, 3
units of platelets that were CMV negative, and 11 units of
platelets that were CMV positive within 30 days after HSCT.Table 2
CMV-Positive Patients
Patient HSCT Date Transfusions Time to CMV Detection* Method of
A Jan 2000 CMV negative 61 Blood - PC
B Nov 2002 CMV negative 31 BAL - PCR
C Jul 2006 CMV negative 49 Blood - PC
D Jun 2007 Leukoreduced 32 Blood - PC
BAL indicates bronchoalveolar lavage.
* Time to CMV detection reported in days after HSCT.DISCUSSION
Transfusion-transmitted CMV can be a potentially fatal
consequence for HSCT recipients. Since the 1980s, CMV-
seronegative transfusion products have been used in these
patients to decrease CMV viremia and disease. It is unclear if
this is still required in the era of universal leukoreduction of
blood products in Canada. Our study demonstrated no dif-
ference in CMV viremia or disease in patients receiving CMV-
negative leukoreduced versus leukoreduced-only blood
products. This study suggests that in the age of universal
leukoreduction in Canada, routine testing of blood products
for CMV may not be warranted for HSCT recipients.
Our data are in accordance with reported results from
other institutions. In a small study of 23 CMV-negative HSCT
recipients from a CMV-negative donor, none of the patients
developed anti-CMV antibodies after being transfused with
CMV untested blood products, indicating that the risk of
transfusion-transmitted CMV is close to zero with leukor-
eduction [22]. These data should be cautiously interpreted,
however, because antibody formation in patients receiving
an HSCT may be impaired due to immunosuppression.
Although our incidence of CMV viremia was low with leu-
koreduction only (1.3%), the risk was still not zero. AlthoughCMV Detection CMV Disease Outcome
R Pneumonitis Respiratory failure, died day 190
Pneumonitis Respiratory failure, died day 35
R No CMV negative after 3 wk of treatment
R No CMV negative after 6 wk of treatment
Table 3
Clinical Outcomes
CMV Negative (n ¼ 89) Leukoreduced (n ¼ 77) P
Total LOS, d (mean  SD) 41.5  20.0 46.8  32.0 .47
Patients who went to ICU, n (%) 15 (16.9) 21 (27.3) .10
Days to neutrophil engraftment* (mean  SD) 19.0  5.9 19.3  5.5 .65
Days to platelet engraftment* (mean  SD) 32.5  53.7 27.2  22.9 .90
100-Day nonrelapse mortality, n (%) 13 (14.6) 9 (11.7) .65
Acute GVHD (overall), n (%) 37 (41.6) 27 (35.1) .39
Acute GVHD (severe), n (%) 9 (10.1) 14 (18.2) .13
Chronic GVHD, n (%) 20 (22.5) 18 (23.4) .52
LOS indicates length of stay; ICU, intensive care unit.
* Absolute neutrophil count >.5  109/L for at least 3 days; platelets >50  109/L with no platelet transfusions for at least 3 days.
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other than transfusion, these possibilities are less likely;
therefore, we assume the transmission to be through trans-
fusion. Seronegative donors still have the potential to pass
CMV DNA to the transfusion recipient, especially in the
window period after infection [23]. CMV testing in this
circumstance will not recognize the donor as CMV positive
because the antibody testing (which is standard practice for
testing CMV in blood donors) will remain negative. This
window period is believed to be days to weeks but has been
reported to be as long as months [24]. This provides an
explanation for the development of CMV viremia, albeit at a
low incidence, even in patients receiving CMV-negative
blood products. The inability of CMV serologic testing to
detect window period donations provides further rationale
for using standard leukoreduced blood products.
Similar to our study, CMV viremia in patients receiving
leukoreduced blood products at the University of Michigan
was not different in patients receiving CMV-negative versus
CMV-untested transfusions [25]. In this study, however, most
patients in the CMV-negative cohort received a mix of CMV-
negative and CMV-untested blood products, making the
results difﬁcult to interpret. In our study, 100% of patients in
the CMV-negative cohort received CMV-negative blood
products.
Although transfusion-transmitted CMV was present in
this study, the mortality related to CMV disease remained
unclear. Two patients who were given CMV-negative andFigure 1. Neutrophil engraftmeleukoreduced blood products developed presumed CMV
disease based on CMV viremia and pulmonary symptoms
thought to be related to CMV pneumonitis. In both cases,
however, concomitant infections (A. fumigatus in 1 and HHV-
6 in the other) may have contributed to the mortality
observed in these patients. CMV disease was not observed in
our cohort of patients receiving CMV-untested leukoreduced
blood products after 2007.
Despite the small number of patients in this study, the
results have important clinical implications. In a transplant
center that has performed 491 allogeneic HSCTs during the
time course of this study, 166 (33.8%) were CMV-negative
donor and recipient pairs. The transfusion-transmitted
CMV incidence was very low in patients receiving leukore-
duced CMV-negative (3.4%) and -untested (1.3%) blood
products, with no signiﬁcant difference in nonrelapse mor-
tality at 100 days after HSCT. In a moderately sized transplant
center, the clinical impact of CMV testing was therefore
negligible in the era of universal leukoreduction. If we esti-
mate the incidence of CMV viremia to be 3% with CMV-
untested blood products as observed in this study, a very
large sample size would be needed in a randomized pro-
spective trial to show a clinically relevant risk reduction.
With an already low incidence of CMV viremia, this would be
impractical and unlikely to change clinical practice.
There are limitations to our study that warrant attention,
predominantly associated with our retrospective design. We
attempted to minimize selection bias by including allnt by transfusion group.
Figure 2. Platelet engraftment by transfusion group.
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HSCTs at The Ottawa Hospital. Second, although our study
provides acute and chronic GVHD rates, the types and
duration of GVHD treatment were not captured. This could
impact the risk of CMV viremia because patients receiving
immunosuppressive treatment for GVHD would be at higher
risk of CMV disease. Third, trends in transplantation practice
may have inﬂuenced our results. General supportive care
measures did not change during the study period. The
practice of universal prophylaxis with acyclovir and the an-
tivirals used for the treatment of CMV were unchanged
throughout the study period, as was the policy of high-
resolution HLA testing. Although no signiﬁcant difference
in baseline characteristics was identiﬁed, a higher proportion
of patients with chronic myelogenous leukemia received
CMV-negative leukoreduced blood products (15.7% versus
2.6%). This is due to the increasing use of tyrosine kinase
inhibitors, eliminating the need for transplant in many of
these patients.Figure 3. Overall survival bThe median age was nonsigniﬁcantly higher in the CMV-
negative leukocyte reduced cohort, as was the use of pe-
ripheral blood as a stem cell source. Furthermore, random
donor platelets were more commonly used in the earlier
cohort of patients receiving leukoreduced CMV-negative
blood products. This likely reﬂects a change in practice
rather than a signiﬁcant difference in the patient pop-
ulations. Single-donor apheresis platelets have always been
preferred to random donor platelets in HSCT recipients and
have become more available in recent years. Our transplant
center has also moved toward a more conservative threshold
for platelet transfusions. These factors together contributed
to the observation that patients receiving leukoreduced-only
blood products received fewer random platelet donor
transfusions. Despite these limitations, to our knowledge,
this is the largest study to compare allogeneic HSCT re-
cipients receiving CMV-negative versus CMV-untested blood
products in the era of universal leukoreduction. A large
randomized control trial would be impractical andwould noty transfusion group.
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would impact clinical outcomes.
In the era of universal leukoreduction of blood products,
this study demonstrates that testing for CMV-negative blood
products is not needed in HSCT recipients. Our ﬁndings have
implications for national health care resource utilization.
Currently, about 47% of donors at Canadian Blood Services are
individually tested for CMV. The cost of the medical supplies
alone for CMV testing at Canadian Blood Services is estimated
to be 745,000 CAD per year (G. Balkar, Canadian Blood Ser-
vices, personal communication, 2013). HSCT recipients
consume a signiﬁcant number of blood products, and elimi-
nating the need for CMV testing for this patient population
nationwide could result in substantial cost savings.
ACKNOWLEDGMENTS
The authors thank the contributions of S. Couban, M.
Seftel, R. Foley, D. Stewart, and J. Sepher from the Canadian
transplant centers in offering information on their CMV
transfusion practices across transplant centers in Canada.
The authors also thank P. Lesley and G. Balkar for information
from the Canadian Blood Services.
Financial disclosure: N. Kekre was supported by a grant
from the Canadian Blood and Marrow Transplant Group
(CBMTG).
Conﬂict of interest statement: There are no conﬂicts to
disclose.
REFERENCES
1. Yazer MH, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage
WBC reduction on the rates of febrile nonhemolytic transfusion
reactions to platelet concentrates and RBC. Transfusion. 2004;44:
10-15.
2. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction de-
creases the incidence of febrile nonhemolytic transfusion reactions to
RBCs. Transfusion. 2004;44:25-29.
3. Vamvakas EC. Meta-analysis of randomized controlled trials of the
efﬁcacy of white cell reduction in preventing- alloimmunization and
refractoriness to random-donor platelet transfusions. Transfus Med Rev.
1998;12:258-270.
4. Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not
allergic reactions to RBCs and platelets after conversion to universal
prestorage leukoreduction. Transfusion. 2004;44:16-24.
5. Heddle NM, Blajchman MA, Meyer RM, et al. A randomized controlled
trial comparing the frequency of acute reactions to plasma-removed
platelets and prestorage WBC-reduced platelets. Transfusion. 2002;42:
556-566.
6. Blajchman MA. The clinical beneﬁts of the leukoreduction of blood
products. J Trauma. 2006;60(6 Suppl.):S83-S90.
7. de Jong MD, Galasso GJ, Gazzard B, et al. Summary of the II Interna-
tional Symposium on Cytomegalovirus. Antiviral Res. 1998;39:141-162.8. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seropre-
valence and demographic characteristics associated with infection. Rev
Med Virol. 2010;20:202-213.
9. Joseph SA, Beliveau C, Muecke CJ, et al. Risk factors for cytomegalovirus
seropositivity in a population of day care educators in Montréal, Can-
ada. Occup Med (Lond). 2005;55:564-567.
10. Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus
infection in seronegative transfusion recipients not receiving exoge-
nous immunosuppression. J Infect Dis. 1988;157:523-529.
11. Vancíková Z, Dvorák P. Cytomegalovirus infection in immunocompe-
tent and immunocompromised individualsda review. Curr Drug
Targets Immune Endocr Metabol Disord. 2001;1:179-187.
12. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia
after bone marrow transplantation. Risk factors and response to ther-
apy. Transplantation. 1993;55:1339-1346.
13. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus
infection after human marrow transplantation. J Infect Dis. 1986;153:
478-488.
14. Saleh AJ, Al Mohareb F, Al Rabiah F, et al. High efﬁcacy and low toxicity
of short-course oral valganciclovir as pre-emptive therapy for he-
matopoietic stem cell transplant cytomegalovirus infection. Hematol
Oncol Stem Cell Ther. 2010;3:116-120.
15. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to
prevent cytomegalovirus disease after allogeneic marrow transplant.
Ann Intern Med. 1993;118:173-178.
16. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune
globulin and seronegative blood products to prevent primary cyto-
megalovirus infection after marrow transplantation. N Engl J Med.
1986;314:1006-1010.
17. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of ﬁltered
leukocyte-reduced and cytomegalovirus (CMV) seronegative blood
products for the prevention of transfusion-associated CMV infection
after marrow transplant. Blood. 1995;86:3598-3603.
18. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cyto-
megalovirus infection after receipt of leukoreduced blood products.
Blood. 2003;101:4195-4200.
19. Diaz-Mitoma F, Leger C, Miller H, et al. Comparison of DNA ampliﬁ-
cation, mRNA ampliﬁcation, and DNA hybridization techniques for
detection of cytomegalovirus in bone marrow transplant recipients.
J Clin Microbiol. 2003;41:5159-5166.
20. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and
puzzle. J Clin Invest. 2011;121:1673-1680.
21. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
22. Thiele T, Krüger W, Zimmermann K, et al. Transmission of cytomega-
lovirus (CMV) infection by leukoreduced blood products not tested for
CMV antibodies: a single-center prospective study in high-risk patients
undergoing allogeneic hematopoietic stem cell transplantation (CME).
Transfusion. 2011;51:2620-2626.
23. Ziemann M, Juhl D, Görg S, Hennig H. The impact of donor cytomeg-
alovirus DNA on transfusion strategies for at-risk patients. Transfusion.
2013;53:2189-2199.
24. Ziemann M, Unmack A, Steppat D, et al. The natural course of primary
cytomegalovirus infection in blood donors. Vox Sang. 2010;99:24-33.
25. Nash T, Hoffmann S, Butch S, et al. Safety of leukoreduced, cytomeg-
alovirus (CMV)-untested components in CMV-negative allogeneic
human progenitor cell transplant recipients. Transfusion. 2012;52:
2270-2272.
